Featured Research

from universities, journals, and other organizations

UK breast cancer mortality rates have fallen faster than in other European countries, study finds

Date:
August 11, 2010
Source:
BMJ-British Medical Journal
Summary:
Population-based breast cancer mortality rates in the UK have fallen steeply in the last two decades -- more than in any other major European country, a new study finds. These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.

Population-based breast cancer mortality rates in the UK have fallen steeply in the last two decades -- more than in any other major European country, finds a study published in the British Medical Journal online. These results challenge claims that survival after breast cancer is worse in the UK than elsewhere in western Europe.

The apparently poor UK survival rates are misleading because of shortcomings in the way cancers are registered in the UK, whereas the population-based mortality rates are reasonably reliable, says an accompanying editorial.

Since the late 1980s, breast cancer mortality rates have been falling in many European countries. This has been largely attributed to the combined effects of early diagnosis, including breast screening, and the effective treatment of breast cancer.

A team of researchers led by Philippe Autier from the International Prevention Research Institute in France, examined changes in breast cancer mortality rates in women living in 30 European countries from 1980 to 2006.

Using World Health Organisation data, mortality rates were calculated for all women and by age group (less than 50 years, 50-69 years and 70 years and over).

From 1989 to 2006, breast cancer mortality decreased by 20% or more in 15 European countries. In the UK, mortality rates fell by about 30%, more than in any other major European country. In France, Finland and Sweden, that have also invested much in breast screening and new cancer drugs, mortality rates decreased by 10-16%.

In central European countries, breast cancer mortality rates did not decline and even increased during the last two decades.

Women aged under 50 showed the biggest reductions in mortality rates, although screening at that age is uncommon. This may reflect better targeting of effective treatments, suggest the authors. They also suggest that the sustained decline observed in many countries seems to indicate that breast cancer mortality will continue to decrease beyond 2006.

The authors call for better data collection to help understand the variations in breast cancer mortality across Europe and action to reduce avoidable breast cancer mortality in central European countries.

In an accompanying editorial, Valerie Beral and Richard Peto, at the University of Oxford, point out that cancer registration in the UK is known to be incomplete and that defects in these data make cancer survival rates appear significantly worse than they really are. By contrast, the registration of death is complete, deaths from breast cancer are well recorded (except at old age), and so population-based mortality trends in middle age are fairly reliable.

They conclude that the rapid decline in UK population-based breast cancer mortality rates in middle age (see graph -- link below) are valid and that failure to make proper allowances for the shortcomings of cancer registration data "may well have led to misleading claims about the supposed inferiority of UK cancer treatment services in general."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "UK breast cancer mortality rates have fallen faster than in other European countries, study finds." ScienceDaily. ScienceDaily, 11 August 2010. <www.sciencedaily.com/releases/2010/08/100811193425.htm>.
BMJ-British Medical Journal. (2010, August 11). UK breast cancer mortality rates have fallen faster than in other European countries, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/08/100811193425.htm
BMJ-British Medical Journal. "UK breast cancer mortality rates have fallen faster than in other European countries, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/08/100811193425.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins